Please use this identifier to cite or link to this item:
Title: Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
Austin Authors: Porter, Laura H;Lawrence, Mitchell G;Ilic, Dragan;Clouston, David;Bolton, Damien M ;Frydenberg, Mark;Murphy, Declan G;Pezaro, Carmel;Risbridger, Gail P;Taylor, Renea A
Affiliation: Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia
Prostate Cancer Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia
School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia
TissuPath, Mount Waverley, Australia
Department of Urology, Austin Health, Heidelberg, Victoria, Australia
Department of Surgery, University of Melbourne, Melbourne, Australia
Department of Surgery, Monash University, Melbourne, Australia
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia
Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
Eastern Health Clinical School, Monash University, Melbourne, Australia
Department of Physiology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia
Issue Date: Oct-2017 2017-03-22
Publication information: European urology 2017; 72(4): 492-495
Abstract: Intraductal carcinoma of the prostate (IDC-P) is associated with poor prognosis. While it is often regarded as a rare pathology, the prevalence of IDC-P remains unclear, with variable reports from small and disparate patient populations. To determine how common IDC-P is across the spectrum of prostate cancer, we conducted a systematic review correlating IDC-P prevalence with prostate cancer risk. Electronic searches of the OVID Medline, PubMed, and Scopus literature databases identified 38 patient cohorts in 24 articles, which were divided between four prostate cancer risk categories (low, moderate, high, and recurrent or metastatic disease). This review, which included radical prostatectomy and prostate biopsy specimens from >7000 patients, revealed an unexpectedly high rate of IDC-P. The IDC-P prevalence increased from 2.1% in low-risk patient cohorts to 23.1%, 36.7%, and 56.0% in moderate-risk, high-risk, and metastatic or recurrent disease risk categories, respectively (p<0.0001). IDC-P was also highly prevalent in tumours following androgen deprivation therapy or chemotherapy (60%). Contrary to common perceptions, this study demonstrates a strong association between IDC-P prevalence and aggressive prostate cancer, with a significantly higher frequency in high-risk disease. Greater recognition and systematic reporting of IDC-P may improve patient risk stratification. Prostate cancer can grow within ducts of the prostate, as well as in prostate tissue. By reviewing all reports describing prostate cancer growing within ducts, we found that it occurs more commonly than many scientists and clinicians appreciate, especially in aggressive prostate cancers. We conclude that there should be more awareness of this pattern of prostate cancer.
DOI: 10.1016/j.eururo.2017.03.013
ORCID: 0000-0002-5145-6783
Journal: European Urology
PubMed URL: 28342640
Type: Journal Article
Subjects: BRCA2 germline mutation
Prostate cancer
Risk stratification
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 30, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.